About

I am pleased to be part of such a dedicated team, with extensive combined experience of developing biological products through to approval and commercialisation. We are focussed on the continued development of emactuzumab as a potentially best-in-class treatment for patients with TGCT and other macrophage-driven pathologies around the globe. This is a critical and exciting stage of the company's journey and we all look forward to pursuing our mission.

Ray Barlow

Chief Executive Officer

Our mission

At SynOx, we understand the power of being in control of your own journey in the treatment of your disease.

Our mission is to establish emactuzumab as a best-in-class drug of choice to address the unmet needs, and improve the quality of life, of as many patients as possible.

By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.

SynOx Therapeutics was established in November 2020 following the licensing from Roche of the exclusive worldwide rights to emactuzumab, a potentially best-in-class CSF-1R monoclonal antibody. Emactuzumab has a well-tolerated safety profile and has shown promising efficacy in patients suffering from TGCT, a rare and debilitating disease that causes significant pain and disability.

SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation. It is backed by a strong syndicate of premier life sciences investors.

Our team

  • Ray Barlow

    Chief Executive Officer

  • Axel Mescheder

    Chief Medical Officer

  • Broes Naeye

    Chief Technology Officer

  • Sarah Clare

    Director of Finance and Operations

  • Sander Veltkamp

    VP Clinical Development and Regulatory Affairs

Board of Directors

  • Ton Logtenberg

    Non-Executive Chairman

  • Ray Barlow

    Chief Executive Officer

  • Ton Logtenberg

    Non-Executive Chairman

  • Ray Barlow

    Chief Executive Officer

  • Dirk Kersten

  • Michaël Vlemmix

  • Carl Kilander

  • Prof. Nick La Thangue

Our investors